fluorouracil has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 62 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The CREATE-X study, conducted in Japan and South Korea, established capecitabine as an adjuvant treatment option for patients with triple negative breast cancer (TNBC) who have residual disease (RD) following neoadjuvant anthracycline or taxane-based chemotherapy." | 8.02 | The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population. ( Bardia, A; Beyerlin, K; Bossuyt, V; Edmonds, C; Ellisen, LW; Fell, GG; Isakoff, SJ; Jimenez, R; Johnson, A; Moy, B; Mulvey, TM; Specht, M; Spring, LM; Zangardi, M, 2021) |
| "Capecitabine is an orally administered prodrug that converts preferentially to 5-fluorouracil within tumors, resulting in enhanced concentrations of 5-fluorouracil in tumor tissue." | 6.82 | Capecitabine-induced leukoencephalopathy in a patient with triple-negative breast cancer: A case report and review of the literature. ( Abu-Shahin, FI; Brown, EN; Liu, L, 2022) |
| "In this series of locally advanced breast cancer, the combination of (FEC100) followed by cisplatin/docetaxel with and without trastuzumab was very active obtaining an impressive rate of pCR, particularly in HER2-positive and triple negative disease, which merits further investigation." | 6.82 | A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer. ( A L-Abdulkarim, H; A L-Tweigeri, T; Abulkhair, O; Ajarim, D; Alawadi, S; AlSayed, A; Ashour, W; Ibrahim, M; Jaafar, H; Khalid, H, 2016) |
| "Zoledronic acid (ZOL) is a nitrogen-containing bisphosphonate that induces osteoclast apoptosis and inhibits bone resorption by inhibiting the mevalonate pathway." | 6.80 | Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study). ( Akazawa, K; Hasegawa, Y; Hayashi, M; Horiguchi, J; Ishikawa, T; Kim, SJ; Kohno, N; Konishi, M; Kubota, T; Miura, D; Miyashita, M; Shigeoka, Y; Suzuki, M; Taguchi, T; Takao, S; Tanino, H; Yamagami, K, 2015) |
| "Following neoadjuvant chemotherapy for breast cancer, postoperative systemic therapy, also called post-neoadjuvant treatment, has been established in defined risk settings." | 6.72 | Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients-sequentially, or better simultaneously? ( Baumann, R; Budach, W; Duma, MN; Dunst, J; Feyer, P; Fietkau, R; Haase, W; Harms, W; Hehr, T; Krug, D; Piroth, MD; Sauer, R; Sedlmayer, F; Souchon, R; Strnad, V, 2021) |
| "Capecitabine has become a standard treatment option for metastatic breast cancer, as a single agent or in combination." | 6.50 | Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature. ( Aftimos, PG; Errihani, H; Mokrim, M; Piccart-Gebhart, M, 2014) |
| " The present study compared the efficacy of six cycles of docetaxel and cyclophosphamide (TC6) with that of three cycles of 5-fluorouracil, epirubicin and cyclophosphamide followed by docetaxel (FEC-D) in Japanese patients with hormone receptor (HR)-negative breast cancer (BC) to identify subtypes requiring anthracycline treatment." | 5.30 | Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101. ( Arioka, H; Chishima, T; Doi, T; Endo, I; Ichikawa, Y; Ishikawa, T; Kida, K; Kosaka, Y; Kuranami, M; Mogaki, M; Morita, S; Narui, K; Nawata, S; Niikura, N; Oba, MS; Ogata, H; Ota, T; Saito, Y; Sasaki, T; Sengoku, N; Shimizu, D; Suto, A; Suzuki, Y; Tanabe, M; Tokuda, Y; Tsugawa, K; Yamada, A, 2019) |
| "A single-arm, multicentre, phase II, open-label study evaluated four 3-weekly cycles of FEC (5-fluorouracil 600 mg/m(2), epirubicin 90 mg/m(2) and cyclophosphamide 600 mg/m(2)) followed by 12 cycles of weekly paclitaxel (80 mg/m(2)) in combination with bevacizumab 10 mg/kg every 2 weeks as neoadjuvant therapy for HER2-negative stage III locally advanced or inflammatory breast carcinoma." | 5.17 | Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer. ( Aitini, E; Bighin, C; Bisagni, G; Clavarezza, M; De Placido, S; Del Mastro, L; Durando, A; Galli, A; Garrone, O; Levaggi, A; Restuccia, E; Saracchini, S; Scalamogna, R; Turazza, M, 2013) |
| "The CREATE-X study, conducted in Japan and South Korea, established capecitabine as an adjuvant treatment option for patients with triple negative breast cancer (TNBC) who have residual disease (RD) following neoadjuvant anthracycline or taxane-based chemotherapy." | 4.02 | The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population. ( Bardia, A; Beyerlin, K; Bossuyt, V; Edmonds, C; Ellisen, LW; Fell, GG; Isakoff, SJ; Jimenez, R; Johnson, A; Moy, B; Mulvey, TM; Specht, M; Spring, LM; Zangardi, M, 2021) |
| "Capecitabine is an orally administered prodrug that converts preferentially to 5-fluorouracil within tumors, resulting in enhanced concentrations of 5-fluorouracil in tumor tissue." | 2.82 | Capecitabine-induced leukoencephalopathy in a patient with triple-negative breast cancer: A case report and review of the literature. ( Abu-Shahin, FI; Brown, EN; Liu, L, 2022) |
| "In this series of locally advanced breast cancer, the combination of (FEC100) followed by cisplatin/docetaxel with and without trastuzumab was very active obtaining an impressive rate of pCR, particularly in HER2-positive and triple negative disease, which merits further investigation." | 2.82 | A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer. ( A L-Abdulkarim, H; A L-Tweigeri, T; Abulkhair, O; Ajarim, D; Alawadi, S; AlSayed, A; Ashour, W; Ibrahim, M; Jaafar, H; Khalid, H, 2016) |
| "Zoledronic acid (ZOL) is a nitrogen-containing bisphosphonate that induces osteoclast apoptosis and inhibits bone resorption by inhibiting the mevalonate pathway." | 2.80 | Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study). ( Akazawa, K; Hasegawa, Y; Hayashi, M; Horiguchi, J; Ishikawa, T; Kim, SJ; Kohno, N; Konishi, M; Kubota, T; Miura, D; Miyashita, M; Shigeoka, Y; Suzuki, M; Taguchi, T; Takao, S; Tanino, H; Yamagami, K, 2015) |
| "Following neoadjuvant chemotherapy for breast cancer, postoperative systemic therapy, also called post-neoadjuvant treatment, has been established in defined risk settings." | 2.72 | Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients-sequentially, or better simultaneously? ( Baumann, R; Budach, W; Duma, MN; Dunst, J; Feyer, P; Fietkau, R; Haase, W; Harms, W; Hehr, T; Krug, D; Piroth, MD; Sauer, R; Sedlmayer, F; Souchon, R; Strnad, V, 2021) |
| "Capecitabine has become a standard treatment option for metastatic breast cancer, as a single agent or in combination." | 2.50 | Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature. ( Aftimos, PG; Errihani, H; Mokrim, M; Piccart-Gebhart, M, 2014) |
| "BACKGROUND Triple negative breast cancer (TNBC) has a more aggressive recurrence." | 1.48 | Triple Negative Breast Cancer Depends on Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-Phosphate Receptor 3 (S1PR3)/Notch Signaling for Metastasis. ( Chang, W; Hu, B; Liang, Y; Wang, S; Zhang, Y, 2018) |
| "From the Korean breast cancer registry database, 1,151 T1c node negative TNBC patients were included in this study." | 1.48 | The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer. ( Gwak, H; Jeon, YW; Kang, EY; Kim, SY; Lee, HJ; Lim, ST; Moon, BI; Nam, SJ; Park, CH; Suh, YJ, 2018) |
| "Irinotecan has synergism with 5-fluorouracil and shows efficacy in advanced breast cancer." | 1.42 | Irinotecan and capecitabine combination chemotherapy in a patient with triple-negative breast cancer relapsed after adjuvant chemotherapy with anthracycline and taxane. ( Cho, JM; Go, SI; Jeon, KN; Kang, JH; Kang, MH; Kim, HG; Kim, MJ; Lee, A; Lee, GW; Lee, JH; Lee, US; Lee, WS, 2015) |
| "In conclusion, patients with breast cancer may experience changes in HR status, HER2 status and tumor phenotype after NCT." | 1.42 | Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study. ( Chen, S; Di, GH; Jiang, YZ; Jin, X; Shao, ZM; Yu, KD, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 44 (70.97) | 24.3611 |
| 2020's | 18 (29.03) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, U | 1 |
| Chashoo, G | 1 |
| Khan, SU | 1 |
| Mahajan, P | 1 |
| Nargotra, A | 1 |
| Mahajan, G | 1 |
| Singh, A | 1 |
| Sharma, A | 1 |
| Mintoo, MJ | 1 |
| Guru, SK | 1 |
| Aruri, H | 1 |
| Thatikonda, T | 1 |
| Sahu, P | 1 |
| Chibber, P | 1 |
| Kumar, V | 1 |
| Mir, SA | 1 |
| Bharate, SS | 1 |
| Madishetti, S | 1 |
| Nandi, U | 1 |
| Singh, G | 1 |
| Mondhe, DM | 1 |
| Bhushan, S | 1 |
| Malik, F | 1 |
| Mignani, S | 1 |
| Vishwakarma, RA | 1 |
| Singh, PP | 1 |
| Luo, Y | 1 |
| Wu, W | 2 |
| Zha, D | 1 |
| Zhou, W | 2 |
| Wang, C | 1 |
| Huang, J | 1 |
| Chen, S | 3 |
| Yu, L | 1 |
| Li, Y | 1 |
| Huang, Q | 1 |
| Zhang, J | 1 |
| Zhang, C | 1 |
| Yang, DL | 1 |
| Zhang, YJ | 1 |
| Lei, J | 1 |
| Li, SQ | 1 |
| He, LJ | 1 |
| Tang, DY | 1 |
| Xu, C | 1 |
| Zhang, LT | 1 |
| Wen, J | 2 |
| Lin, HK | 1 |
| Li, HY | 1 |
| Chen, ZZ | 1 |
| Xu, ZG | 1 |
| Liu, L | 1 |
| Brown, EN | 1 |
| Abu-Shahin, FI | 1 |
| Miyajima, N | 1 |
| Ragab Eissa, I | 1 |
| Abdelmoneim, M | 1 |
| Naoe, Y | 1 |
| Ichinose, T | 1 |
| Matsumura, S | 1 |
| Bustos-Villalobos, I | 1 |
| Mukoyama, N | 1 |
| Morimoto, D | 1 |
| Shibata, M | 1 |
| Takeuchi, D | 1 |
| Tsunoda, N | 1 |
| Kikumori, T | 1 |
| Tanaka, M | 4 |
| Kodera, Y | 1 |
| Kasuya, H | 1 |
| Yang, L | 1 |
| Haga, Y | 1 |
| Nishimura, A | 1 |
| Tsujii, Y | 1 |
| Tanahashi, S | 1 |
| Tsujino, H | 1 |
| Higashisaka, K | 1 |
| Tsutsumi, Y | 1 |
| Wang, H | 1 |
| Shan, X | 1 |
| Peng, Y | 1 |
| Azman, AA | 1 |
| Siok-Fong, C | 1 |
| Rajab, NF | 1 |
| Md Zin, RR | 1 |
| Ahmad Daud, NN | 1 |
| Mohamad Hanif, EA | 1 |
| Milczarek, M | 1 |
| Cierpiał, T | 1 |
| Kiełbasiński, P | 1 |
| Małecka-Giełdowska, M | 1 |
| Świtalska, M | 1 |
| Wietrzyk, J | 1 |
| Mazur, M | 1 |
| Wiktorska, K | 1 |
| Varshavsky-Yanovsky, AN | 1 |
| Goldstein, LJ | 1 |
| de Boo, L | 1 |
| Cimino-Mathews, A | 1 |
| Lubeck, Y | 1 |
| Daletzakis, A | 1 |
| Opdam, M | 1 |
| Sanders, J | 1 |
| Hooijberg, E | 1 |
| van Rossum, A | 1 |
| Loncova, Z | 1 |
| Rieder, D | 1 |
| Trajanoski, Z | 1 |
| Vollebergh, M | 1 |
| Sobral-Leite, M | 1 |
| van de Vijver, K | 1 |
| Broeks, A | 1 |
| van der Wiel, R | 1 |
| van Tinteren, H | 3 |
| Linn, S | 1 |
| Horlings, HM | 1 |
| Kok, M | 1 |
| Asleh, K | 1 |
| Brauer, HA | 1 |
| Sullivan, A | 1 |
| Lauttia, S | 1 |
| Lindman, H | 2 |
| Nielsen, TO | 1 |
| Joensuu, H | 2 |
| Thompson, EA | 1 |
| Chumsri, S | 1 |
| Teraoka, S | 1 |
| Sato, E | 1 |
| Narui, K | 3 |
| Yamada, A | 3 |
| Fujita, T | 1 |
| Yamada, K | 1 |
| Oba, M | 1 |
| Ishikawa, T | 4 |
| Piroth, MD | 1 |
| Krug, D | 1 |
| Sedlmayer, F | 1 |
| Duma, MN | 1 |
| Baumann, R | 1 |
| Budach, W | 1 |
| Dunst, J | 1 |
| Feyer, P | 1 |
| Fietkau, R | 1 |
| Haase, W | 1 |
| Harms, W | 1 |
| Hehr, T | 1 |
| Souchon, R | 1 |
| Strnad, V | 1 |
| Sauer, R | 1 |
| Muhammad, N | 1 |
| Tan, CP | 1 |
| Nawaz, U | 1 |
| Wang, J | 1 |
| Wang, FX | 1 |
| Nasreen, S | 1 |
| Ji, LN | 1 |
| Mao, ZW | 1 |
| Beyerlin, K | 1 |
| Jimenez, R | 1 |
| Zangardi, M | 1 |
| Fell, GG | 1 |
| Edmonds, C | 1 |
| Johnson, A | 1 |
| Bossuyt, V | 1 |
| Specht, M | 1 |
| Mulvey, TM | 1 |
| Moy, B | 1 |
| Ellisen, LW | 1 |
| Isakoff, SJ | 1 |
| Bardia, A | 1 |
| Spring, LM | 1 |
| Barkovskaya, A | 1 |
| Goodwin, CM | 1 |
| Seip, K | 1 |
| Hilmarsdottir, B | 1 |
| Pettersen, S | 1 |
| Stalnecker, C | 1 |
| Engebraaten, O | 1 |
| Briem, E | 1 |
| Der, CJ | 1 |
| Moestue, SA | 1 |
| Gudjonsson, T | 1 |
| Maelandsmo, GM | 1 |
| Prasmickaite, L | 1 |
| Zheng, M | 1 |
| Mei, Z | 1 |
| Junaid, M | 1 |
| Tania, M | 1 |
| Fu, J | 1 |
| Chen, HC | 1 |
| Khan, MA | 1 |
| Ata, FK | 1 |
| Yalcin, S | 1 |
| Schultze, E | 1 |
| Buss, J | 1 |
| Coradini, K | 1 |
| Begnini, KR | 1 |
| Guterres, SS | 1 |
| Collares, T | 1 |
| Beck, RCR | 1 |
| Pohlmann, AR | 1 |
| Seixas, FK | 1 |
| Wang, S | 1 |
| Liang, Y | 1 |
| Chang, W | 1 |
| Hu, B | 1 |
| Zhang, Y | 1 |
| Lim, ST | 1 |
| Park, CH | 1 |
| Kim, SY | 1 |
| Nam, SJ | 1 |
| Kang, EY | 1 |
| Moon, BI | 1 |
| Lee, HJ | 1 |
| Jeon, YW | 1 |
| Gwak, H | 1 |
| Suh, YJ | 1 |
| Hilton, J | 1 |
| Stober, C | 1 |
| Mazzarello, S | 1 |
| Vandermeer, L | 1 |
| Fergusson, D | 1 |
| Hutton, B | 1 |
| Clemons, M | 1 |
| Wang, Q | 1 |
| Li, C | 1 |
| Tang, P | 1 |
| Ji, R | 1 |
| Ren, YX | 1 |
| Hao, S | 1 |
| Jin, X | 2 |
| Ye, FG | 1 |
| Gong, Y | 1 |
| Jiang, YZ | 2 |
| Shao, ZM | 2 |
| Shimizu, D | 1 |
| Tanabe, M | 2 |
| Sasaki, T | 1 |
| Oba, MS | 2 |
| Morita, S | 2 |
| Nawata, S | 1 |
| Kida, K | 2 |
| Mogaki, M | 1 |
| Doi, T | 1 |
| Tsugawa, K | 2 |
| Ogata, H | 1 |
| Ota, T | 1 |
| Kosaka, Y | 1 |
| Sengoku, N | 1 |
| Kuranami, M | 1 |
| Niikura, N | 1 |
| Saito, Y | 1 |
| Suzuki, Y | 1 |
| Suto, A | 1 |
| Arioka, H | 1 |
| Chishima, T | 1 |
| Ichikawa, Y | 2 |
| Endo, I | 2 |
| Tokuda, Y | 1 |
| Clavarezza, M | 1 |
| Turazza, M | 1 |
| Aitini, E | 1 |
| Saracchini, S | 1 |
| Garrone, O | 1 |
| Durando, A | 1 |
| De Placido, S | 1 |
| Bisagni, G | 1 |
| Levaggi, A | 1 |
| Bighin, C | 1 |
| Restuccia, E | 1 |
| Scalamogna, R | 1 |
| Galli, A | 1 |
| Del Mastro, L | 1 |
| Zurrida, S | 1 |
| Bagnardi, V | 2 |
| Curigliano, G | 2 |
| Mastropasqua, MG | 1 |
| Orecchia, R | 1 |
| Disalvatore, D | 1 |
| Greco, M | 1 |
| Cataliotti, L | 1 |
| D'Aiuto, G | 1 |
| Talakhadze, N | 1 |
| Goldhirsch, A | 3 |
| Viale, G | 2 |
| Tariq, K | 1 |
| Rana, F | 1 |
| Samiian, L | 1 |
| Kilkenny, JW | 1 |
| Khan, R | 1 |
| Latif, N | 1 |
| Pivot, X | 1 |
| Cortés, J | 1 |
| Elias, A | 1 |
| Cesari, R | 1 |
| Khosravan, R | 1 |
| Collier, M | 1 |
| Huang, X | 1 |
| Cataruozolo, PE | 1 |
| Kern, KA | 1 |
| Gross, E | 1 |
| Meul, C | 1 |
| Raab, S | 1 |
| Propping, C | 1 |
| Avril, S | 1 |
| Aubele, M | 1 |
| Gkazepis, A | 1 |
| Schuster, T | 1 |
| Grebenchtchikov, N | 1 |
| Schmitt, M | 1 |
| Kiechle, M | 1 |
| Meijer, J | 1 |
| Vijzelaar, R | 1 |
| Meindl, A | 1 |
| van Kuilenburg, AB | 1 |
| Takahashi, K | 1 |
| Inagaki, A | 1 |
| Wanibuchi, H | 1 |
| Izumi, Y | 1 |
| Miura, K | 1 |
| Nagayama, K | 1 |
| Shiota, M | 1 |
| Iwao, H | 1 |
| Liao, Y | 1 |
| Fan, Y | 2 |
| Wan, Y | 1 |
| Li, J | 1 |
| Peng, L | 1 |
| Rocca, A | 1 |
| Bravaccini, S | 1 |
| Scarpi, E | 1 |
| Mangia, A | 1 |
| Petroni, S | 1 |
| Puccetti, M | 1 |
| Medri, L | 1 |
| Serra, L | 1 |
| Ricci, M | 1 |
| Cerasoli, S | 1 |
| Biglia, N | 1 |
| Maltoni, R | 1 |
| Giunchi, DC | 1 |
| Gianni, L | 1 |
| Tienghi, A | 1 |
| Brandi, M | 1 |
| Faedi, M | 2 |
| Sismondi, P | 1 |
| Paradiso, A | 1 |
| Silvestrini, R | 1 |
| Amadori, D | 1 |
| Foedermayr, M | 1 |
| Sebesta, M | 1 |
| Rudas, M | 1 |
| Berghoff, AS | 1 |
| Promberger, R | 1 |
| Preusser, M | 1 |
| Dubsky, P | 1 |
| Fitzal, F | 1 |
| Gnant, M | 1 |
| Steger, GG | 1 |
| Weltermann, A | 1 |
| Zielinski, CC | 1 |
| Zach, O | 1 |
| Bartsch, R | 1 |
| Watanabe, Y | 1 |
| Maeda, I | 1 |
| Oikawa, R | 1 |
| Tsuchiya, K | 1 |
| Miyoshi, Y | 1 |
| Itoh, F | 1 |
| Ohta, T | 1 |
| Wu, CE | 1 |
| Chen, SC | 1 |
| Lin, YC | 1 |
| Lo, YF | 1 |
| Hsueh, S | 1 |
| Chang, HK | 1 |
| Gasparini, P | 1 |
| Cascione, L | 1 |
| Fassan, M | 1 |
| Lovat, F | 1 |
| Guler, G | 1 |
| Balci, S | 1 |
| Irkkan, C | 1 |
| Morrison, C | 1 |
| Croce, CM | 1 |
| Shapiro, CL | 1 |
| Huebner, K | 1 |
| Jiao, S | 1 |
| Wu, M | 1 |
| Ye, F | 1 |
| Tang, H | 1 |
| Xie, X | 2 |
| Gonzalez-Angulo, AM | 1 |
| Akcakanat, A | 1 |
| Liu, S | 1 |
| Green, MC | 1 |
| Murray, JL | 1 |
| Chen, H | 1 |
| Palla, SL | 1 |
| Koenig, KB | 1 |
| Brewster, AM | 1 |
| Valero, V | 1 |
| Ibrahim, NK | 1 |
| Moulder-Thompson, S | 1 |
| Litton, JK | 1 |
| Tarco, E | 1 |
| Moore, J | 1 |
| Flores, P | 1 |
| Crawford, D | 1 |
| Dryden, MJ | 1 |
| Symmans, WF | 1 |
| Sahin, A | 1 |
| Giordano, SH | 1 |
| Pusztai, L | 1 |
| Do, KA | 1 |
| Mills, GB | 1 |
| Hortobagyi, GN | 1 |
| Meric-Bernstam, F | 1 |
| Fushimi, K | 1 |
| Tanabe, N | 1 |
| Takami, M | 1 |
| Mokrim, M | 1 |
| Aftimos, PG | 1 |
| Errihani, H | 1 |
| Piccart-Gebhart, M | 1 |
| Masuda, N | 1 |
| Higaki, K | 1 |
| Takano, T | 1 |
| Matsunami, N | 1 |
| Morimoto, T | 1 |
| Ohtani, S | 1 |
| Mizutani, M | 1 |
| Miyamoto, T | 1 |
| Kuroi, K | 1 |
| Ohno, S | 1 |
| Toi, M | 1 |
| Vollebergh, MA | 1 |
| Lips, EH | 1 |
| Nederlof, PM | 1 |
| Wessels, LF | 1 |
| Wesseling, J | 1 |
| Vd Vijver, MJ | 1 |
| de Vries, EG | 1 |
| Jonkers, J | 1 |
| Hauptmann, M | 1 |
| Rodenhuis, S | 1 |
| Linn, SC | 2 |
| De Iuliis, F | 1 |
| Salerno, G | 1 |
| Taglieri, L | 1 |
| Vicinanza, R | 1 |
| Lanza, R | 1 |
| Scarpa, S | 1 |
| Lam, SW | 1 |
| de Groot, SM | 1 |
| Honkoop, AH | 1 |
| Jager, A | 1 |
| ten Tije, AJ | 1 |
| Bos, MM | 1 |
| van den Bosch, J | 1 |
| Kroep, JR | 1 |
| Braun, JJ | 1 |
| Boven, E | 1 |
| Anan, K | 1 |
| Yoshinaga, Y | 1 |
| Maeda, S | 1 |
| Yamaguchi, Y | 1 |
| Hayashi, M | 2 |
| Kamata, Y | 1 |
| Mashino, K | 1 |
| Yamamoto, Y | 1 |
| Nishimura, J | 1 |
| Matsuo, S | 1 |
| Toyoshima, S | 1 |
| Tamura, K | 1 |
| Mitsuyama, S | 1 |
| Lee, WY | 1 |
| Hsu, KF | 1 |
| Chiang, TA | 1 |
| Chen, CJ | 1 |
| Coradini, D | 1 |
| Biganzoli, E | 1 |
| Ardoino, I | 1 |
| Ambrogi, F | 1 |
| Boracchi, P | 1 |
| Demicheli, R | 1 |
| Daidone, MG | 1 |
| Moliterni, A | 1 |
| Lee, A | 1 |
| Go, SI | 1 |
| Lee, WS | 1 |
| Lee, US | 1 |
| Kim, MJ | 1 |
| Kang, MH | 1 |
| Lee, GW | 1 |
| Kim, HG | 1 |
| Kang, JH | 1 |
| Jeon, KN | 1 |
| Cho, JM | 1 |
| Lee, JH | 1 |
| Bahhnassy, A | 1 |
| Mohanad, M | 1 |
| Shaarawy, S | 1 |
| Ismail, MF | 1 |
| El-Bastawisy, A | 1 |
| Ashmawy, AM | 1 |
| Zekri, AR | 1 |
| Yu, KD | 1 |
| Di, GH | 1 |
| Cancello, G | 1 |
| Sangalli, C | 1 |
| Montagna, E | 1 |
| Dellapasqua, S | 1 |
| Sporchia, A | 1 |
| Iorfida, M | 1 |
| Barberis, M | 1 |
| Veronesi, P | 1 |
| Luini, A | 1 |
| Intra, M | 1 |
| Colleoni, M | 1 |
| Dieci, MV | 1 |
| Mathieu, MC | 1 |
| Guarneri, V | 1 |
| Conte, P | 1 |
| Delaloge, S | 1 |
| Andre, F | 1 |
| Goubar, A | 1 |
| Asano, Y | 1 |
| Kashiwagi, S | 1 |
| Onoda, N | 1 |
| Noda, S | 1 |
| Kawajiri, H | 1 |
| Takashima, T | 1 |
| Ohsawa, M | 1 |
| Kitagawa, S | 1 |
| Hirakawa, K | 1 |
| A L-Tweigeri, T | 1 |
| AlSayed, A | 1 |
| Alawadi, S | 1 |
| Ibrahim, M | 1 |
| Ashour, W | 1 |
| Jaafar, H | 1 |
| Abulkhair, O | 1 |
| A L-Abdulkarim, H | 1 |
| Khalid, H | 1 |
| Ajarim, D | 1 |
| Hasegawa, Y | 1 |
| Tanino, H | 1 |
| Horiguchi, J | 1 |
| Miura, D | 1 |
| Takao, S | 1 |
| Kim, SJ | 1 |
| Yamagami, K | 1 |
| Miyashita, M | 1 |
| Konishi, M | 1 |
| Shigeoka, Y | 1 |
| Suzuki, M | 1 |
| Taguchi, T | 1 |
| Kubota, T | 1 |
| Akazawa, K | 1 |
| Kohno, N | 1 |
| de Oliveira, SF | 1 |
| Ganzinelli, M | 1 |
| Chilà, R | 1 |
| Serino, L | 1 |
| Maciel, ME | 1 |
| Urban, Cde A | 1 |
| de Lima, RS | 1 |
| Cavalli, IJ | 1 |
| Generali, D | 1 |
| Broggini, M | 1 |
| Damia, G | 1 |
| Ribeiro, EM | 1 |
| Yen, CF | 1 |
| Lam, HB | 1 |
| Kellokumpu-Lehtinen, PL | 1 |
| Huovinen, R | 1 |
| Jukkola-Vuorinen, A | 1 |
| Tanner, M | 1 |
| Kokko, R | 1 |
| Ahlgren, J | 1 |
| Auvinen, P | 1 |
| Lahdenperä, O | 1 |
| Kosonen, S | 1 |
| Villman, K | 1 |
| Nyandoto, P | 1 |
| Nilsson, G | 1 |
| Poikonen-Saksela, P | 1 |
| Kataja, V | 1 |
| Junnila, J | 1 |
| Bono, P | 1 |
| Xu, BH | 1 |
| Yuan, P | 1 |
| Ma, F | 1 |
| Wang, JY | 1 |
| Ding, XY | 1 |
| Zhang, P | 1 |
| Li, Q | 1 |
| Cai, RG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC) OTT 15-04[NCT02688803] | Phase 4 | 2 participants (Actual) | Interventional | 2016-08-31 | Completed | ||
| Phase II, Open Label, Neoadjuvant Study of Bevacizumab in Patients With Inflammatory or Locally Advanced Breast Cancer[NCT00559845] | Phase 2 | 56 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Randomized Phase 2 Study Of SU011248 Versus Standard-Of-Care For Patients With Previously Treated, Advanced, Triple Receptor Negative (ER, PR, HER2) Breast Cancer[NCT00246571] | Phase 2 | 217 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Open Label Randomized Clinical Trial of Standard Neoadjuvant Chemotherapy (Paclitaxel Followed by FEC) Versus the Combination of Paclitaxel and RAD001 Followed by FEC in Women With Triple Receptor-Negative Breast Cancer (CRAD001C24101)[NCT00499603] | Phase 2 | 62 participants (Actual) | Interventional | 2007-07-31 | Active, not recruiting | ||
| Multicenter, Randomized, Phase II Study of Neoadjuvant Chemotherapy Associated or Not With Zoledronate and Atorvastatin in Triple Negative Breast Cancers - YAPPETIZER Study[NCT03358017] | Phase 2 | 54 participants (Actual) | Interventional | 2018-03-05 | Completed | ||
| A Randomized Phase III Study Comparing Docetaxel Followed by Cyclophosphamide, Epirubicin and 5-FU to Docetaxel With Capecitabine Followed by Cyclophosphamide, Epirubicin and Capecitabine as Adjuvant Treatment for Early Breast Cancer[NCT00114816] | Phase 3 | 1,500 participants (Anticipated) | Interventional | 2004-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Objective response rate was defined as the percentage of participants with a Complete Response (CR) or Partial Response (PR) as defined by the Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as the disappearance of all target lesions; PR was defined as a 30% decrease in sum of longest diameter of target lesions. (NCT00559845)
Timeframe: Up to 7.5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab | 59.0 |
An adverse event was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. (NCT00559845)
Timeframe: Up to 7.5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab | 100.0 |
Pathological complete response was defined as absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. (NCT00559845)
Timeframe: Up to 7.5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab | 23.2 |
Rate of breast conversing surgery is defined as percentage of participants who achieved breast conversing surgery out of the ITT population without inflammatory breast cancer, as these participants received mastectomy irrespective of their response to neoadjuvant treatment. (NCT00559845)
Timeframe: Up to 7.5 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Breast-conserving | Breast-conserving Plus Axillary Dissection | |
| Bevacizumab | 17.0 | 13.2 |
Disease-free interval was defined as the time from enrollment until recurrence of tumor or death from any cause, and was estimated using the Kaplan-Meier method. The percentage of participants without events at Months 12, 24, 36, 48, and 60 is presented. (NCT00559845)
Timeframe: Months 12, 24, 36, 48, and 60
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| 12 Months | 24 Months | 36 Months | 48 Months | 60 Months | |
| Bevacizumab | 92.2 | 84.3 | 80.4 | 76.5 | 76.5 |
Time in months from the date of randomization to date of death due to any cause. OS was calculated as (date of death minus randomization date plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death). (NCT00246571)
Timeframe: Baseline until death (up to 3 years after first dose of study medication)
| Intervention | months (Median) |
|---|---|
| Sunitinib | 9.4 |
| Standard of Care | 10.5 |
Probability that the participants will survive at end of 1 year from the first dose of study treatment. Calculated using data collected from baseline until death (up to 3 years after first dose of study medication). Probability calculated from Kaplan-Meier estimate. (NCT00246571)
Timeframe: Baseline until death (up to 3 years after first dose of study medication)
| Intervention | ratio (Number) |
|---|---|
| Sunitinib | 0.376 |
| Standard of Care | 0.446 |
Blood samples were collected to enumerate the number of total CECs and sVEGFR1, sVEGFR2 and sVEGFR3 protein expression and/or cellular viability. (NCT00246571)
Timeframe: Days 1 and 15 of Cycles 1, 2 and 3, Day 1 of Cycles 4 and 5, and every odd cycle thereafter, and EOT/withdrawal
| Intervention | cells/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=42, 48) | Cycle 1, Day 15 (n=28, 37) | Cycle 2, Day 1 (n=33, 35) | Cycle 2, Day 15 (n=7, 5) | Cycle 3, Day 1 (n=27, 25) | Cycle 3, Day 15 (n=4, 1) | Cycle 4, Day 1 (n=3, 5) | Cycle 5, Day 1 (n=2, 2) | EOT (n=18, 18) | |
| Standard of Care | 1176.92 | 1199.32 | 1048.31 | 852.96 | 509.75 | 231.80 | 976.79 | 2031.67 | 1087.94 |
| Sunitinib | 944.67 | 630 | 512.39 | 1310.86 | 390.09 | 923.85 | 169.24 | 145.68 | 477.83 |
Blood samples were collected to enumerate the number of total CTCs and insulin growth factor 1R positive (IGF-1R+) CTCs (NCT00246571)
Timeframe: Days 1 and 15 of Cycles 1, 2 and 3, Day 1 of Cycles 4 and 5, and every odd cycle thereafter, and EOT/withdrawal
| Intervention | cells/7.5 mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=33, 28) | Cycle 1, Day 15 (n=20, 16) | Cycle 2, Day 1 (n=19, 17) | Cycle 2, Day 15 (n=3, 7) | Cycle 3, Day 1 (n=8, 15) | Cycle 3, Day 15 (n=2, 4) | Cycle 4, Day 1 (n=2, 5) | Cycle 5, Day 1 (n=2, 3) | EOT (n=17,4) | |
| Standard of Care | 17.71 | 10.69 | 3.18 | 0.86 | 10.60 | 0 | 0.60 | 0.33 | 3 |
| Sunitinib | 119.76 | 183.60 | 189 | 33.33 | 36.50 | 40.50 | 61 | 19.50 | 55 |
(NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=54) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | 0.02 | 29.4 | 32.3 | 33.4 | 28.5 | 40.4 | 30.9 | 36.1 | 21.3 |
(NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=54) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | 0.14 | 94.9 | 94.4 | 91.6 | 78.6 | 105 | 82.2 | 84.2 | 63.6 |
Ctrough = plasma concentration of SU012662 prior to study drug administration, dose corrected using the following formula Intended Dose/Actual Dose, where Actual Dose: the dose the participant received over the last 10 consecutive days and Intended Dose: the starting dose per study protocol. (NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=ND) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | NA | 29.9 | 37.2 | 37.3 | 39.8 | 40.1 | 38.7 | 41.9 | 28.6 |
Ctrough = plasma concentration of sunitinib prior to study drug administration, dose corrected using the following formula Intended Dose/Actual Dose, where Actual Dose: the dose the participant received over the last 10 consecutive days and Intended Dose: the starting dose per study protocol. (NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=ND) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | NA | 67.5 | 73.4 | 69.8 | 69.3 | 65.3 | 68.7 | 58.4 | 64.0 |
Ctrough = plasma concentration of total drug (Sunitinib + SU012662) prior to study drug administration dose corrected using the following formula Intended Dose/Actual Dose, where Actual Dose: the dose the participant received over the last 10 consecutive days and Intended Dose: the starting dose per study protocol. (NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=ND) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | NA | 97.4 | 111 | 107 | 109 | 105 | 107 | 100 | 92.5 |
Time in months from the first documentation of objective tumor response (CR or PR) to objective tumor progression or death. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response. (NCT00246571)
Timeframe: Time from first response to disease progression up to 3 years from first dose
| Intervention | months (Median) | |
|---|---|---|
| Core radiology assessment (n=3,7) | Investigator's assessment (n=10,12) | |
| Standard of Care | NA | 4.6 |
| Sunitinib | 3.0 | 3.6 |
(NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=54) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | 0.12 | 65.53 | 62.09 | 58.20 | 50.03 | 64.61 | 51.25 | 48.07 | 42.23 |
Plasma concentrations of sKIT were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5 and 7), and EOT/withdrawal
| Intervention | pg/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=83, 64) | Cycle 2 Day 1 (n=66, 48) | Cycle 3 Day 1 (n=49, 35) | Cycle 4 Day 1 (n=33, 27) | Cycle 5 Day 1 (n=28, 19) | Cycle 7 Day 1 (n=9, 8) | End Of Treatment (n=49, 11) | |
| Standard of Care | 62232.81 | 65843.75 | 63582.86 | 62885.19 | 54811.05 | 56237.50 | 72854.55 |
| Sunitinib | 61862.65 | 44987.88 | 30855.10 | 25887.88 | 21696.07 | 18166.67 | 25004.08 |
Plasma concentrations of sPlGF were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5 and 7), and EOT/withdrawal
| Intervention | pg/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=15, 11) | Cycle 2 Day 1 (n=11, 9) | Cycle 3 Day 1 (n=5, 4) | Cycle 4 Day 1 (n=2, 3) | Cycle 5 Day 1 (n=1, 3) | Cycle 7 Day 1 (n=1, 1) | End Of Treatment (n=5, 0) | |
| Standard of Care | 37.23 | 36.24 | 40.08 | 33.23 | 51.83 | 38.50 | 0 |
| Sunitinib | 36.96 | 168.05 | 72.16 | 144.60 | 118.30 | 176.60 | 87.54 |
Plasma concentrations of sVEGF-A were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5, and 7), and EOT/withdrawal
| Intervention | pg/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=83, 66) | Cycle 2 Day 1 (n=67, 50) | Cycle 3 Day 1 (n=49, 37) | Cycle 4 Day 1 (n=33, 28) | Cycle 5 Day 1 (n=28, 20) | Cycle 7 Day 1 (n=9, 10) | End Of Treatment (n=49, 12) | |
| Standard of Care | 151.49 | 170.43 | 129.31 | 129.88 | 126.97 | 115.58 | 94.76 |
| Sunitinib | 152.28 | 455.17 | 265.56 | 274.94 | 324.09 | 241.78 | 294.66 |
Plasma concentrations of sVEGFR3 were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5, and 7), and EOT/withdrawal
| Intervention | pg/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=83, 64) | Cycle 2 Day 1 (n=66, 48) | Cycle 3 Day 1 (n=48, 35) | Cycle 4 Day 1 (n=32, 27) | Cycle 5 Day 1 (n=28, 20) | Cycle 7 Day 1 (n=9, 9) | End Of Treatment (n=48, 10) | |
| Standard of Care | 25857.19 | 24515.83 | 29034.86 | 27929.63 | 32949 | 32004.44 | 29194 |
| Sunitinib | 24124.82 | 16299.70 | 14459.38 | 13702.81 | 16345.36 | 24795.56 | 26746.46 |
"Time in months from start of study treatment to first documentation of objective tumor progression (per RECIST) or death due to any cause. PFS was calculated as (first event date minus first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was Death)." (NCT00246571)
Timeframe: Baseline, every 6 weeks until disease progression or death (up to 3 years from first dose)
| Intervention | Months (Median) | |
|---|---|---|
| Core radiology laboratory assessment | Investigator's assessment | |
| Standard of Care | 2.7 | 2.5 |
| Sunitinib | 2.0 | 1.7 |
Objective response based assessment of confirmed response (CR) or confirmed partial response (PR) according to RECIST. CR are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. PR are those with a greater than or equal to (≥) 30% decrease in the sum of the longest dimensions (SLD) of the target lesions taking as a reference the baseline SLD. (NCT00246571)
Timeframe: Baseline until response or disease progression (up to 3 years from first dose)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Core radiology laboratory assessment | Investigator's assessment | |
| Standard of Care | 6.7 | 11.5 |
| Sunitinib | 2.7 | 8.8 |
Number of participants with inhibition of the PI3K/PTEN/AKT pathway at 48 hours after the start of treatment, regardless of the status of the pathway at the time of randomization. Molecular changes (inhibition/activation) of the PI3K/PTEN/AKT pathway evaluated using reverse phase protein arrays (RPPA) where fine-needle aspirations (FNAs) from the primary breast cancer obtained pretreatment, and at 48 hours. Bioinformatics cluster analysis of arrays used to define molecular changes as inhibition or activation where pathways called 'active' with presence of 2 or more phosphorilated pathway proteins (pAKT, pmTOR, pGSK3, pS6K1, pS6), and 'inhibited' with one or none phosphorilated pathway proteins present. (NCT00499603)
Timeframe: 48 hours after start of treatment
| Intervention | participants (Number) |
|---|---|
| Paclitaxel + FEC | 27 |
| Paclitaxel + RAD001 + FEC | 22 |
Radiographic criteria of response based on regional ultrasound examination (decrease in size of the primary tumor and/or fatty replacement in regional lymph nodes), and includes partial response and complete response. A decrease in size of the product of the two largest dimensions =/> 50% considered a partial response (PR), and a complete disappearance of the primary tumor by physical exam and or ultrasound and normalization of the lymph nodes by ultrasound will be considered a complete clinical response (CR). Stable Disease (SD) is carcinoma neither decreasing nor increasing in extent or severity, and Progression of disease (PD) defined as 30% increase in size primary tumor and/or lymph nodes on physical exam and/or ultrasound. (NCT00499603)
Timeframe: 12 weeks
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CR | PR | SD | PD | |
| Paclitaxel + FEC | 3 | 5 | 16 | 3 |
| Paclitaxel + RAD001 + FEC | 0 | 11 | 11 | 1 |
Radiographic criteria of response based on regional ultrasound examination (decrease in size of the primary tumor and/or fatty replacement in regional lymph nodes), and includes partial response and complete response. A decrease in size of the product of the two largest dimensions =/> 50% considered a partial response (PR), and a complete disappearance of the primary tumor by physical exam and or ultrasound and normalization of the lymph nodes by ultrasound will be considered a complete clinical response (CR). Stable Disease (SD) is carcinoma neither decreasing nor increasing in extent or severity, and Progression of disease (PD) defined as 30% increase in size primary tumor and/or lymph nodes on physical exam and/or ultrasound. (NCT00499603)
Timeframe: 24 weeks
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CR | PR | SD | PD | |
| Paclitaxel + FEC | 4 | 16 | 7 | 0 |
| Paclitaxel + RAD001 + FEC | 2 | 11 | 7 | 3 |
5 reviews available for fluorouracil and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Capecitabine-induced leukoencephalopathy in a patient with triple-negative breast cancer: A case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, | 2022 |
Circular RNAs in the chemoresistance of triple-negative breast cancer: A systematic review.
Topics: Biomarkers; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neopla | 2023 |
The potential roles of lncRNA TINCR in triple negative breast cancer.
Topics: Fluorouracil; Humans; Neoplasm Recurrence, Local; RNA, Long Noncoding; Triple Negative Breast Neopla | 2023 |
Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients-sequentially, or better simultaneously?
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecit | 2021 |
Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 2014 |
24 trials available for fluorouracil and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Prote | 2020 |
Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Doc | 2020 |
Neoadjuvant Chemotherapy With Anthracycline-Based Regimen for BRCAness Tumors in Triple-Negative Breast Cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Chemothe | 2020 |
Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Docetaxel; Doxorubici | 2018 |
Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo | 2019 |
Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2013 |
High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cyclophosphamide; D | 2013 |
Efficacy of neoadjuvant cisplatin and oral capecitabine in triple-negative breast cancers: a pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluo | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, A | 2013 |
Acceptable but limited efficacy of capecitabine-based doublets in the first-line treatment of metastatic triple-negative breast cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Docetaxel; Drug Therapy, Combinatio | 2013 |
Benefit from anthracyclines in relation to biological profiles in early breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Disease- | 2014 |
BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Capecitabine; Cyclophosp | 2014 |
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Everolimu | 2014 |
A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cyclop | 2014 |
Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cyclophos | 2015 |
Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cyclophosp | 2015 |
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2015 |
Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Epirubicin; Fem | 2016 |
A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide | 2016 |
Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dip | 2015 |
BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Bridged- | 2016 |
Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, | 2017 |
Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Ci | 2013 |
33 other studies available for fluorouracil and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model.
Topics: Animals; Antineoplastic Agents; Breast; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinas | 2017 |
Synthesis and biological evaluation of novel ligustrazine-chalcone derivatives as potential anti-triple negative breast cancer agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chalcone; Dose-Response | 2021 |
Discovery of fused benzimidazole-imidazole autophagic flux inhibitors for treatment of triple-negative breast cancer.
Topics: Autophagy; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Triple Negative | 2022 |
S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model.
Topics: Animals; Antimetabolites, Antineoplastic; CD8-Positive T-Lymphocytes; Drug Combinations; Fluorouraci | 2021 |
Fluorouracil exacerbates alpha-crystallin B chain-mediated cell migration in triple-negative breast cancer cell lines.
Topics: alpha-Crystallin B Chain; Cell Line, Tumor; Cell Movement; Fluorouracil; Humans; Triple Negative Bre | 2023 |
An Organofluorine Isoselenocyanate Analogue of Sulforaphane Affects Antimetabolite 5-Fluorouracil's Anticancer Activity: A Perspective for New Combinatory Therapy in Triple-Negative Breast Cancer.
Topics: Animals; Antimetabolites; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Fl | 2023 |
Role of Capecitabine in Early Breast Cancer.
Topics: Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Fluorouracil; Humans; Triple Negative Breast | 2020 |
Multiaction Platinum(IV) Prodrug Containing Thymidylate Synthase Inhibitor and Metabolic Modifier against Triple-Negative Breast Cancer.
Topics: Apoptosis; Cell Line, Tumor; Coordination Complexes; DNA Damage; Drug Liberation; Enzyme Inhibitors; | 2020 |
The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuva | 2021 |
Detection of phenotype-specific therapeutic vulnerabilities in breast cells using a CRISPR loss-of-function screen.
Topics: Antineoplastic Agents; Cell Proliferation; CRISPR-Cas Systems; Drug Screening Assays, Antitumor; Epi | 2021 |
Synergistic Role of Thymoquinone on Anticancer Activity of 5-Fluorouracil in Triple Negative Breast Cancer Cells.
Topics: Apoptosis; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Fluorouracil; Humans; Triple Negativ | 2022 |
The Cisplatin, 5-fluorouracil, Irinotecan, and Gemcitabine Treatment in Resistant 2D and 3D Model Triple Negative Breast Cancer Cell Line: ABCG2 Expression Data.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Proliferation; | 2022 |
Tretinoin-loaded lipid-core nanocapsules overcome the triple-negative breast cancer cell resistance to tretinoin and show synergistic effect on cytotoxicity induced by doxorubicin and 5-fluororacil.
Topics: Antineoplastic Agents; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Resistance, Neoplasm; Drug | 2017 |
Triple Negative Breast Cancer Depends on Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-Phosphate Receptor 3 (S1PR3)/Notch Signaling for Metastasis.
Topics: Animals; Cell Line, Tumor; Doxorubicin; Drug Synergism; Female; Fluorouracil; Heterografts; Humans; | 2018 |
The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; | 2018 |
A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cyclophosphamide; Databases, Genet | 2018 |
Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Somatic copy number changes in DPYD are associated with lower risk of recurrence in triple-negative breast cancers.
Topics: Antimetabolites, Antineoplastic; BRCA1 Protein; Chromosome Fragile Sites; Dihydrouracil Dehydrogenas | 2013 |
Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line.
Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; | 2013 |
Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; CpG | 2013 |
Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2014 |
microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Docetaxe | 2014 |
BikDDA, a mutant of Bik with longer half-life expression protein, can be a novel therapeutic gene for triple-negative breast cancer.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Biomarkers, Tumor; Cell Line, Tumor; Chemot | 2014 |
[A retrospective study of tegafur/uracil compared with cyclophosphamide, methotrexate, and fluorouracil as adjuvant chemotherapy in patients with node-negative, triple-negative breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamid | 2014 |
Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Prote | 2014 |
Elderly woman with triple-negative metastatic breast cancer successfully treated with metronomic capecitabine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Brain Neoplasms; Capecitab | 2014 |
[Effect of weekly paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide as neoadjuvant treatment for patients with triple-negative and luminal-type breast cancer - a multicenter study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epi | 2015 |
Phellinus linteus extract induces autophagy and synergizes with 5-fluorouracil to inhibit breast cancer cell growth.
Topics: Agaricales; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autoph | 2015 |
Irinotecan and capecitabine combination chemotherapy in a patient with triple-negative breast cancer relapsed after adjuvant chemotherapy with anthracycline and taxane.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Cam | 2015 |
Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Di | 2015 |
Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined | 2015 |
Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Agents; Azacitidine; Carcinoma, Ductal, Breast; Carcinoma, | 2016 |
Chemotherapy With CMF for Triple-Negative Breast Cancer With Carcinoma Erysipelatoides.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Fluorouracil; H | 2016 |